Skip to the page

Data / Drug companies / Onesource Specialty Pharma Limited

Onesource Specialty Pharma Limited: 55 products in the FDA NDC directory, labeler code 83270

Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).

Onesource Specialty Pharma Limited (labeler code 83270) lists 55 products in the FDA National Drug Code Directory, covering 21 finished drugs by generic name. By type: 55 prescription drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on October 12, 2026.

The request: Watch Onesource Specialty Pharma Limited (FDA labeler code 83270): each new product listing and each discontinued product. $10 of work on sign-up, no card.

SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.

Labeler code
83270
Products in commercial distribution
55
Packages
55
Finished drugs by generic name
21
Prescription products
55
Over the counter products
0
Controlled substance products
Schedule IV 8
Flagged as original packager
53 of 53 products that carry the flag
Started marketing in the last 12 months
34
Earliest marketing start
August 14, 2015
openFDA record search
api.fda.gov

Products by marketing category

Share of the company's products in commercial distribution.

Marketing categoryProductsShare
Generic drugs (ANDA)5498.2%
New drug applications (NDA)11.8%

Products by type

TypeProductsShare
Prescription drugs55100%

Drugs it lists

Finished drugs by generic name, with how many companies list each.

Dosage forms

Dosage formProductsShare
Injection, solution2240%
Injection, powder, for solution1629.1%
Injection1221.8%
Injection, powder, lyophilized, for solution47.3%
Capsule11.8%

Pharmacologic classes

FDA established pharmacologic classes of its products.

Newest products

By marketing start date.

ProductProduct NDCDosage formMarketing categoryMarketing start
Nafcillin83270-316Injection, powder, for solutionGeneric drugs (ANDA)October 12, 2026
VePesid83270-451CapsuleNew drug applications (NDA)May 29, 2026
Metoprolol83270-177InjectionGeneric drugs (ANDA)April 30, 2026
Levothyroxine Sodium83270-008Injection, powder, lyophilized, for solutionGeneric drugs (ANDA)April 27, 2026
Levothyroxine Sodium83270-007Injection, powder, lyophilized, for solutionGeneric drugs (ANDA)April 27, 2026
Levothyroxine Sodium83270-006Injection, powder, lyophilized, for solutionGeneric drugs (ANDA)April 27, 2026
Ampicillin83270-315Injection, powder, for solutionGeneric drugs (ANDA)February 27, 2026
Ampicillin83270-314Injection, powder, for solutionGeneric drugs (ANDA)February 27, 2026
Ampicillin83270-313Injection, powder, for solutionGeneric drugs (ANDA)February 27, 2026
Ampicillin83270-312Injection, powder, for solutionGeneric drugs (ANDA)February 27, 2026
Ampicillin83270-311Injection, powder, for solutionGeneric drugs (ANDA)February 27, 2026
Labetalol hydrochloride83270-179InjectionGeneric drugs (ANDA)February 27, 2026
Labetalol hydrochloride83270-178InjectionGeneric drugs (ANDA)February 27, 2026
Midazolam83270-176Injection, solutionGeneric drugs (ANDA)February 27, 2026
Midazolam83270-175Injection, solutionGeneric drugs (ANDA)February 27, 2026
Midazolam83270-174Injection, solutionGeneric drugs (ANDA)February 27, 2026
Midazolam83270-173Injection, solutionGeneric drugs (ANDA)February 27, 2026
Midazolam83270-172Injection, solutionGeneric drugs (ANDA)February 27, 2026
Midazolam83270-171Injection, solutionGeneric drugs (ANDA)February 27, 2026
Midazolam83270-170Injection, solutionGeneric drugs (ANDA)February 27, 2026
Thiamine Hydrochloride83270-004Injection, solutionGeneric drugs (ANDA)February 27, 2026
Nafcillin sodium83270-310Injection, powder, for solutionGeneric drugs (ANDA)February 20, 2026
Nafcillin sodium83270-309Injection, powder, for solutionGeneric drugs (ANDA)February 20, 2026
Sumatriptan83270-152Injection, solutionGeneric drugs (ANDA)February 2, 2026
Sumatriptan83270-151Injection, solutionGeneric drugs (ANDA)February 2, 2026

CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.